carmustine has been researched along with Diffuse Large B-Cell Lymphoma in 63 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 9.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens." | 7.80 | Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. ( Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY, 2014) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 7.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 5.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens." | 3.80 | Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. ( Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY, 2014) |
| "In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity." | 3.74 | Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 3.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "Patients with Hodgkin lymphoma (HL) had a higher response rate compared to those with diffuse large B cell lymphoma (DLBCL) (63% vs." | 1.38 | Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. ( Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K, 2012) |
| "Melphalan dose was used as surrogate for the entire regimen." | 1.35 | Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. ( Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF, 2008) |
| "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy." | 1.32 | Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. ( Chen, CL; Chiu, CF; Chow, KC; Liaw, YC; Shen, YC; Yeh, SP, 2004) |
| "on post-surgical spontaneous metastases of a non-immunogenic tumour." | 1.28 | Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour. ( Acerbis, G; Cleris, L; Formelli, F; Parmiani, G; Rodolfo, M, 1992) |
| "Procarbazine and BCNU were given for 5 months before conception and throughout the first and second trimesters, and streptozotocin was given throughout the third trimester." | 1.27 | Successful pregnancy following continuous treatment with combination chemotherapy before conception and throughout pregnancy. ( Chudley, AE; Schapira, DV, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (19.05) | 18.7374 |
| 1990's | 7 (11.11) | 18.2507 |
| 2000's | 18 (28.57) | 29.6817 |
| 2010's | 20 (31.75) | 24.3611 |
| 2020's | 6 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Arshad, S | 1 |
| Fang, X | 1 |
| Ahn, KW | 2 |
| Kaur, M | 1 |
| Scordo, M | 1 |
| Sauter, CS | 1 |
| Furqan, F | 1 |
| Awan, FT | 1 |
| Hamadani, M | 2 |
| Qasrawi, A | 1 |
| Arora, R | 1 |
| Ramlal, R | 1 |
| Munker, R | 1 |
| Hildebrandt, GC | 1 |
| Jagadeesh, D | 1 |
| Majhail, NS | 1 |
| He, Y | 1 |
| Litovich, C | 1 |
| Ahmed, S | 1 |
| Aljurf, M | 1 |
| Bacher, U | 1 |
| Badawy, SM | 1 |
| Bejanyan, N | 1 |
| Cairo, M | 1 |
| Cerny, J | 1 |
| Epperla, N | 1 |
| Farhadfar, N | 1 |
| Freytes, CO | 1 |
| Gale, RP | 1 |
| Haverkos, B | 1 |
| Hossain, N | 1 |
| Inwards, D | 1 |
| Kamble, RT | 1 |
| Kenkre, VP | 1 |
| Lazarus, HM | 2 |
| Lazaryan, A | 1 |
| Lekakis, L | 1 |
| Mei, M | 1 |
| Murthy, HS | 1 |
| Mussetti, A | 1 |
| Nathan, S | 1 |
| Nishihori, T | 1 |
| Olsson, RF | 1 |
| Ramakrishnan Geethakumari, P | 1 |
| Savani, BN | 1 |
| Yared, JA | 1 |
| Fenske, TS | 1 |
| Kharfan-Dabaja, MA | 1 |
| Sureda, A | 2 |
| Charifa, A | 1 |
| Paulson, N | 1 |
| Levy, L | 1 |
| Perincheri, S | 1 |
| Lee, A | 1 |
| McNiff, JM | 1 |
| Ko, CJ | 1 |
| Alencar, AJ | 1 |
| Moskowitz, CH | 2 |
| Steinhardt, MJ | 1 |
| Krummenast, FC | 1 |
| Rosenwald, A | 2 |
| Gerhard-Hartmann, E | 1 |
| Heidemeier, A | 1 |
| Einsele, H | 1 |
| Topp, MS | 1 |
| Duell, J | 1 |
| Chen, AI | 1 |
| Leonard, JT | 1 |
| Okada, CY | 1 |
| Gay, ND | 1 |
| Chansky, K | 1 |
| Fan, G | 1 |
| Dunlap, JB | 1 |
| Raess, PW | 1 |
| Braziel, RM | 1 |
| Stentz, A | 1 |
| Maziarz, RT | 1 |
| Lugtenburg, PJ | 1 |
| Zijlstra, JM | 1 |
| Doorduijn, JK | 1 |
| Böhmer, LH | 1 |
| Hoogendoorn, M | 1 |
| Berenschot, HW | 1 |
| Beeker, A | 1 |
| van der Burg-de Graauw, NC | 1 |
| Schouten, HC | 1 |
| Bilgin, YM | 1 |
| Kersten, MJ | 1 |
| Koene, HR | 1 |
| Herbers, AHE | 1 |
| de Jong, D | 1 |
| Hijmering, N | 1 |
| Lam, KH | 1 |
| Chiţu, D | 1 |
| Brouwer, RE | 1 |
| van Imhoff, GW | 1 |
| Vose, JM | 2 |
| Carter, S | 1 |
| Burns, LJ | 1 |
| Ayala, E | 1 |
| Press, OW | 1 |
| Stadtmauer, EA | 1 |
| Mineshi, S | 1 |
| Ambinder, R | 1 |
| Fenske, T | 1 |
| Horowitz, M | 1 |
| Fisher, R | 1 |
| Tomblyn, M | 1 |
| Briones, J | 1 |
| Novelli, S | 1 |
| García-Marco, JA | 1 |
| Tomás, JF | 1 |
| Bernal, T | 1 |
| Grande, C | 4 |
| Canales, MA | 1 |
| Torres, A | 1 |
| Moraleda, JM | 2 |
| Panizo, C | 2 |
| Jarque, I | 1 |
| Palmero, F | 1 |
| Hernández, M | 1 |
| González-Barca, E | 2 |
| López, D | 1 |
| Caballero, D | 2 |
| Burnette, BL | 1 |
| Jentoft, MA | 1 |
| Porrata, LF | 2 |
| Boyce, TG | 1 |
| Witzig, TE | 1 |
| Shin, HJ | 1 |
| Lee, WS | 1 |
| Lee, HS | 1 |
| Kim, H | 1 |
| Lee, GW | 1 |
| Song, MK | 1 |
| Kim, JS | 1 |
| Yhim, HY | 1 |
| Chung, JS | 1 |
| Auger-Quittet, S | 1 |
| Duny, Y | 1 |
| Daures, JP | 1 |
| Quittet, P | 1 |
| Rancea, M | 1 |
| Will, A | 1 |
| Borchmann, P | 1 |
| Monsef, I | 1 |
| Engert, A | 1 |
| Skoetz, N | 1 |
| Pardal, E | 1 |
| Coronado, M | 1 |
| Martín, A | 1 |
| Marín-Niebla, A | 1 |
| Bello, JL | 1 |
| Conde, E | 3 |
| Hernández, MT | 2 |
| Arranz, R | 3 |
| Bargay, J | 1 |
| Pérez-Ceballos, E | 1 |
| Montes-Moreno, S | 1 |
| Caballero, MD | 2 |
| Fruchart, C | 1 |
| Tilly, H | 1 |
| Morschhauser, F | 1 |
| Ghesquières, H | 1 |
| Bouteloup, M | 1 |
| Fermé, C | 1 |
| Van Den Neste, E | 1 |
| Bordessoule, D | 1 |
| Bouabdallah, R | 1 |
| Delmer, A | 1 |
| Casasnovas, RO | 1 |
| Ysebaert, L | 2 |
| Ciappuccini, R | 1 |
| Briere, J | 2 |
| Gisselbrecht, C | 4 |
| Ancochea, Á | 1 |
| Salar, A | 1 |
| García-Pallarols, F | 1 |
| Gimeno, E | 1 |
| Fernández-Rodriguez, C | 1 |
| Sánchez-González, B | 1 |
| Caimi, PF | 1 |
| William, BM | 1 |
| Silva Rondon, CH | 1 |
| Fu, P | 1 |
| Cooper, BW | 1 |
| Campagnaro, EL | 1 |
| Gerson, SL | 1 |
| Reese-Koc, J | 1 |
| Fox, R | 1 |
| Creger, RJ | 1 |
| de Lima, M | 2 |
| Hertzberg, M | 1 |
| Gandhi, MK | 1 |
| Trotman, J | 1 |
| Butcher, B | 1 |
| Taper, J | 1 |
| Johnston, A | 1 |
| Gill, D | 1 |
| Ho, SJ | 1 |
| Cull, G | 1 |
| Fay, K | 1 |
| Chong, G | 1 |
| Grigg, A | 2 |
| Lewis, ID | 1 |
| Milliken, S | 1 |
| Renwick, W | 1 |
| Hahn, U | 1 |
| Filshie, R | 1 |
| Kannourakis, G | 1 |
| Watson, AM | 1 |
| Warburton, P | 1 |
| Wirth, A | 1 |
| Seymour, JF | 1 |
| Hofman, MS | 1 |
| Hicks, RJ | 1 |
| Costa, LJ | 1 |
| Micallef, IN | 1 |
| Inwards, DJ | 1 |
| Johnston, PB | 1 |
| Litzow, MR | 1 |
| Ansell, SM | 1 |
| Derenzini, E | 1 |
| Musuraca, G | 1 |
| Fanti, S | 1 |
| Stefoni, V | 1 |
| Tani, M | 1 |
| Alinari, L | 1 |
| Venturini, F | 1 |
| Gandolfi, L | 1 |
| Baccarani, M | 1 |
| Zinzani, PL | 1 |
| Precupanu, CM | 1 |
| Girodet, J | 1 |
| Mariani, P | 1 |
| Zanni, M | 1 |
| Mathiot, C | 1 |
| Escande, MC | 1 |
| Brault, P | 1 |
| Decaudin, D | 1 |
| Stewart, DA | 1 |
| Bahlis, N | 1 |
| Mansoor, A | 1 |
| Blumenfeld, Z | 2 |
| Zuckerman, T | 2 |
| Linch, DC | 3 |
| Yung, L | 1 |
| Smith, P | 1 |
| Maclennan, K | 1 |
| Jack, A | 1 |
| Hancock, B | 1 |
| Cunningham, D | 1 |
| Hoskin, P | 1 |
| Qian, W | 2 |
| Holte, H | 2 |
| Boesen, AM | 1 |
| Browett, P | 1 |
| Trneny, M | 1 |
| Cuccuini, W | 1 |
| Mounier, N | 1 |
| Voelker, HU | 1 |
| Sundstrom, C | 1 |
| Cogliatti, S | 1 |
| Hirchaud, E | 1 |
| Bron, D | 1 |
| Soulier, J | 1 |
| Gaulard, P | 1 |
| Houlgatte, R | 1 |
| Thieblemont, C | 1 |
| Moore, S | 1 |
| Kayani, I | 1 |
| Peggs, K | 1 |
| Lowry, L | 1 |
| Thomson, K | 1 |
| Ardeshna, K | 1 |
| Papageorgiou, SG | 1 |
| Diamantopoulos, P | 1 |
| Levidou, G | 1 |
| Angelopoulou, MK | 1 |
| Economopoulou, P | 1 |
| Efthimiou, A | 1 |
| Constantinou, N | 1 |
| Katsigiannis, A | 1 |
| Korkolopoulou, P | 1 |
| Pappa, V | 1 |
| Economopoulou, C | 1 |
| Georgiou, G | 1 |
| Dimou, M | 1 |
| Tsirigotis, P | 1 |
| Kyrtsonis, MC | 1 |
| Kotsianidis, I | 1 |
| Kalpadakis, C | 1 |
| Dimopoulos, MA | 1 |
| Beris, P | 1 |
| Meletis, J | 1 |
| Pangalis, GA | 1 |
| Dervenoulas, J | 1 |
| Panayiotidis, P | 1 |
| Vassilakopoulos, TP | 1 |
| Bierman, PJ | 1 |
| Loberiza, FR | 1 |
| Enke, C | 1 |
| Hankins, J | 1 |
| Bociek, RG | 1 |
| Chan, WC | 1 |
| Weisenburger, DD | 1 |
| Armitage, JO | 1 |
| Huang, HC | 1 |
| Cheng, AL | 1 |
| Lin, CW | 1 |
| Kuo, SH | 1 |
| Porcar Ramells, C | 1 |
| Clemente González, C | 1 |
| García Parés, D | 1 |
| Guardia Sánchez, R | 1 |
| Pérez Ayuso, MJ | 1 |
| García-Bragado Dalmau, F | 1 |
| Pérez-Simón, JA | 1 |
| Iriondo, A | 1 |
| Lahuerta, JJ | 3 |
| Sierra, J | 1 |
| Marín, J | 1 |
| Gandarillas, M | 2 |
| Zuazu, J | 1 |
| Rubio, V | 1 |
| Fernández de Sevilla, A | 1 |
| Carreras, E | 1 |
| García-Conde, J | 1 |
| García-Laraña, J | 1 |
| Vidal, MJ | 1 |
| Rifón, J | 1 |
| Pérez-Equiza, C | 1 |
| Varela, R | 1 |
| García Ruíz, JC | 1 |
| Albó, C | 2 |
| Cabrera, R | 1 |
| San Miguel, JF | 1 |
| García, J | 1 |
| Lizasoain, M | 1 |
| Sanz, F | 1 |
| Blystad, AK | 1 |
| Delabie, J | 1 |
| Kvaløy, S | 1 |
| Vålerhaugen, H | 1 |
| Ikonomou, I | 1 |
| Kvalheim, G | 1 |
| Shen, YC | 1 |
| Chiu, CF | 1 |
| Chow, KC | 1 |
| Chen, CL | 1 |
| Liaw, YC | 1 |
| Yeh, SP | 1 |
| Wójcik, B | 1 |
| Kowalczyk, JR | 1 |
| Chybicka, A | 1 |
| Wachowiak, J | 1 |
| Drabko, K | 1 |
| Zaucha-Prazmo, A | 1 |
| Choma, M | 1 |
| Gorczyńska, E | 1 |
| Toporski, J | 1 |
| Turkiewicz, D | 1 |
| Kałwak, K | 1 |
| Pieczonka, A | 1 |
| Boruczkowski, D | 1 |
| Crowther, H | 1 |
| Collins, D | 1 |
| Antonenas, V | 1 |
| McGurgan, M | 1 |
| Kerridge, I | 1 |
| Gottlieb, D | 1 |
| Bradstock, K | 1 |
| Hagberg, H | 1 |
| Benaroush, M | 1 |
| Krishnan, A | 1 |
| Nademanee, A | 1 |
| Fung, HC | 1 |
| Raubitschek, AA | 1 |
| Molina, A | 1 |
| Yamauchi, D | 1 |
| Rodriguez, R | 1 |
| Spielberger, RT | 1 |
| Falk, P | 1 |
| Palmer, JM | 1 |
| Forman, SJ | 1 |
| Mateos, MV | 1 |
| Fernández-Rañada, JM | 1 |
| Alonso, N | 1 |
| García Vela, JA | 1 |
| Garzón, S | 1 |
| Rodríguez, J | 2 |
| Portlock, CS | 1 |
| Schapira, DV | 1 |
| Chudley, AE | 1 |
| D'Incalci, M | 1 |
| Torti, L | 1 |
| Damia, G | 1 |
| Erba, E | 1 |
| Morasca, L | 1 |
| Garattini, S | 1 |
| Brice, P | 1 |
| Pautier, P | 1 |
| Marolleau, JP | 1 |
| Castaigne, S | 1 |
| Gryn, J | 1 |
| Gordon, R | 1 |
| Bapat, A | 1 |
| Goldman, N | 1 |
| Goldberg, J | 1 |
| Vitolo, U | 2 |
| Cortellazzo, S | 1 |
| Liberati, AM | 1 |
| Freilone, R | 2 |
| Falda, M | 1 |
| Bertini, M | 2 |
| Botto, B | 2 |
| Cinieri, S | 1 |
| Levis, A | 1 |
| Locatelli, F | 1 |
| Lovisone, E | 1 |
| Marmont, F | 1 |
| Pizzuti, M | 1 |
| Rossi, A | 2 |
| Viero, P | 2 |
| Barbui, T | 2 |
| Grignani, F | 1 |
| Resegotti, L | 1 |
| Vaughan Hudson, B | 1 |
| Anderson, L | 1 |
| Vaughan Hudson, G | 1 |
| Cortelazzo, S | 1 |
| Bellavita, P | 1 |
| Marchioli, R | 1 |
| Marfisi, RM | 1 |
| Rambaldi, A | 1 |
| Popat, U | 1 |
| Przepiork, D | 1 |
| Champlin, R | 1 |
| Pugh, W | 1 |
| Amin, K | 1 |
| Mehra, R | 1 |
| Giralt, S | 1 |
| Romaguera, J | 1 |
| Rodriguez, A | 1 |
| Preti, A | 1 |
| Andersson, B | 1 |
| Khouri, I | 1 |
| Claxton, D | 1 |
| Donato, M | 1 |
| Anderlini, P | 1 |
| Gajewski, J | 1 |
| Cabanillas, F | 1 |
| van Besien, K | 1 |
| Deconinck, E | 1 |
| Lamy, T | 1 |
| Foussard, C | 1 |
| Gaillard, F | 1 |
| Delwail, V | 1 |
| Colombat, P | 1 |
| Casassus, P | 1 |
| Lemevel, A | 1 |
| Brion, A | 1 |
| Milpied, N | 1 |
| Capello, D | 1 |
| Vivenza, D | 1 |
| Zagonel, V | 1 |
| Gloghini, A | 1 |
| Novero, D | 1 |
| Parvis, G | 1 |
| Calvi, R | 1 |
| Ariatti, C | 1 |
| Milan, I | 1 |
| Boccomini, C | 1 |
| Pregno, P | 1 |
| Orsucci, L | 1 |
| Palestro, G | 1 |
| Saglio, G | 1 |
| Carbone, A | 1 |
| Gallo, E | 1 |
| Gaidano, G | 1 |
| Goldkuhl, C | 1 |
| Ekman, T | 1 |
| Wiklund, T | 1 |
| Telhaug, R | 1 |
| Bennett, JM | 3 |
| Bakemeier, RF | 1 |
| Carbone, PP | 2 |
| Ezdinli, E | 2 |
| Lenhard, RE | 3 |
| Adler, S | 1 |
| Shimaoka, K | 1 |
| Han, T | 1 |
| Tsukada, Y | 1 |
| Johnson, GJ | 1 |
| Pocock, SJ | 1 |
| Durant, JR | 2 |
| Gams, RA | 1 |
| Bartolucci, AA | 1 |
| Dorfman, RF | 1 |
| Ezdinli, EZ | 1 |
| Costello, W | 1 |
| Horton, J | 1 |
| Amorisi, EL | 1 |
| Stolbach, L | 1 |
| Wolter, J | 1 |
| Loeb, V | 1 |
| Dorfman, R | 1 |
| Chan, YK | 1 |
| Acerbis, G | 1 |
| Cleris, L | 1 |
| Rodolfo, M | 1 |
| Parmiani, G | 1 |
| Formelli, F | 1 |
| Marsh, JC | 1 |
| DeConti, RC | 1 |
| Hubbard, SP | 1 |
| De Vita, VT | 1 |
| Canellos, GP | 1 |
| Schein, PJ | 1 |
| Chabner, BA | 1 |
| Bagley, CM | 1 |
| Young, RC | 1 |
| Aungst, CW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMTCTN0401)[NCT00329030] | Phase 3 | 224 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Phase II Study for Safety and Efficacy of BEB (Bendamustine, Etoposide, Busulfan) Conditioning Regimen for ASCT in Non-Hodgkin's Lymphoma[NCT02836639] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | ||
| Targeted Intensification by a Preparative Regimen for Patients With High-grade B-Cell Lymphoma Utilizing Standard-dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-dose BEAM Followed by Autologous Stem Cell Transpl[NCT00689169] | Phase 2 | 75 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941] | 52 participants (Actual) | Interventional | 2005-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mucositis severity will be scored per the modified Oral Mucositis Assessment Scale (OMAS) scoring system on a scale of 0 - 4, where 0 equals normal mucosa and 4 equals severe mucosa. (NCT00329030)
Timeframe: Day 21
| Intervention | scores on a scale (Median) |
|---|---|
| B-BEAM | 0.72 |
| R-BEAM | 0.31 |
(NCT00329030)
Timeframe: Day 100 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 100 | 2 years | |
| B-BEAM | 69.9 | 48.5 |
| R-BEAM | 71.0 | 43.9 |
Hematologic function will be defined as ANC > 1,500 neutrophils/μL, hemoglobin > 10 g/dL without transfusion support, and platelet count > 100,000/μL without transfusion support. (NCT00329030)
Timeframe: 100 days, 1 year
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 100 | 1 year | |
| B-BEAM | 34.8 | 64.0 |
| R-BEAM | 38.5 | 58.9 |
Tests to be performed on peripheral blood include CD2, CD3, CD4, CD8, CD19, CD3+/CD25+, CD45 RA/RO, CD56+/CD3-. (NCT00329030)
Timeframe: 1 year
| Intervention | cells/uL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CD2 (cells/uL) | CD3 (cells/uL) | CD4 (cells/uL) | CD8 (cells/uL) | CD19 (cells/uL) | CD3+/CD25+ (cells/uL) | CD45RA (cells/uL) | CD45RO (cells/uL) | CD56+/CD3- (cells/uL) | |
| B-BEAM | 1006.0 | 921.8 | 342.8 | 558.5 | 143.4 | 112.2 | 469.3 | 476.2 | 125.1 |
| R-BEAM | 1024.9 | 990.3 | 286.1 | 697.7 | 140.8 | 118.0 | 579.8 | 727.8 | 130.5 |
Tests to be performed on peripheral blood for quantitative immunoglobulins include IgM, IgG and IgA. (NCT00329030)
Timeframe: 1 year
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| IgA (mg/dL) | IgG (mg/dL) | IgM (mg/dL) | |
| B-BEAM | 68.5 | 619.6 | 51.0 |
| R-BEAM | 85.0 | 643.8 | 79.0 |
(NCT00329030)
Timeframe: 1 year
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 1 Infection | 2 Infections | 3 Infections | 4 Infections | 5 Infections | 6-10 Infections | >10 Infections | |
| B-BEAM | 38 | 14 | 5 | 3 | 1 | 6 | 0 |
| R-BEAM | 35 | 11 | 7 | 4 | 0 | 2 | 1 |
The time to this event is measured from randomization. Deaths without relapse/progression are considered as a competing risk. Surviving patients with no history of relapse/progression are censored at time of last follow-up. (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 39.6 | 44.2 |
| R-BEAM | 40.7 | 47.4 |
Time to neutrophil recovery will be the first of two consecutive days of > 500 neutrophils/μL following the expected nadir. (NCT00329030)
Timeframe: Day 28 and Day 60
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 28 | Day 60 | |
| B-BEAM | 96.1 | 96.1 |
| R-BEAM | 93.5 | 95.3 |
The event is death from any cause. The time to this event is the time from randomization to death or last follow-up. Surviving patients are censored at the time of last observation (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 68.5 | 60.1 |
| R-BEAM | 73.7 | 66.3 |
(NCT00329030)
Timeframe: 100 and 180 days
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 100 | Day 180 | |
| B-BEAM | 83.5 | 84.5 |
| R-BEAM | 82.2 | 83.2 |
Patients are considered a failure for this endpoint if they die, relapse/progress, or receive anti-lymphoma therapy, other than post-transplant consolidative localized radiation (maximum 3 sites) to sites of prior bulk disease pre-transplant (> 3cm). The time to this event is the time from randomization until death, relapse/progression, receipt of anti-lymphoma therapy, or last follow up, whichever comes first. (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 53.2 | 48.6 |
| R-BEAM | 56.6 | 49.0 |
TRM is defined as death occurring in a patient from causes other than relapse or progression (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 5.9 | 5.9 |
| R-BEAM | 2.9 | 3.9 |
5 reviews available for carmustine and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials, Phase III as Topic; Cyc | 2021 |
Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherap | 2014 |
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carmustine; Cyclophosphamide; Cytara | 2002 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
22 trials available for carmustine and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Rituximab-PECC induction followed by
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aut | 2019 |
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2013 |
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyt | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2014 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2017 |
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabin | 2008 |
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2010 |
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2013 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2006 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Com | 2008 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1997 |
Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carm | 2000 |
Age-adjusted chemotherapy for primary central-nervous system lymphoma--a pilot study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervou | 2002 |
Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group.
Topics: Bleomycin; Carmustine; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug T | 1976 |
Multiple agent chemotherapy for advanced histiocytic lymphoma.
Topics: Adult; Aged; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin | 1976 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
Topics: Carmustine; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Therapy, Combin | 1977 |
Treatment of histiocytic and mixed lymphomas: a comparison of two, three and four drug chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Drug Evaluation; Drug | 1978 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
37 other studies available for carmustine and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Central Nervous Syste | 2023 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, | 2020 |
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort S | 2020 |
Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Vessels; Carmustine; Cyclophosph | 2020 |
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2022 |
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cycloph | 2018 |
Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biops | 2014 |
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2014 |
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyta | 2015 |
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Dis | 2008 |
Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined C | 2009 |
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carmustine; Combined Modality Therapy | 2009 |
Repeated spontaneous pregnancies and successful deliveries after repeated autologous stem cell transplantation and GnRH-agonist treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosph | 2010 |
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide | 2012 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu | 2013 |
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmusti | 2003 |
[Bacteremia due to Capnocytophaga spp.: two cases].
Topics: 4-Quinolones; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremi | 2003 |
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 2004 |
Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
Topics: Adult; Antineoplastic Agents, Alkylating; Carmustine; Cyclooxygenase 2; Fatal Outcome; Female; Human | 2004 |
[Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; | 2004 |
Successful autologous peripheral blood stem cell harvest and transplant in a patient with cold agglutinins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryoglobulins; Cytarabine; Humans; Lymph | 2006 |
Spontaneous pregnancy and normal delivery after repeated autologous bone marrow transplantation and GnRH agonist treatment.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 2007 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
Successful pregnancy following continuous treatment with combination chemotherapy before conception and throughout pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Fema | 1984 |
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Cyclophosphamide; Dacarbazine; Dr | 1983 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyt | 1994 |
Pentostatin increases the acute toxicity of high dose cyclophosphamide.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cis | 1993 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 1997 |
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cyta | 1997 |
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1998 |
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2002 |
1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
Topics: Carmustine; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Lar | 1975 |
Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.
Topics: Animals; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administratio | 1992 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |